Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
June-2015 Volume 11 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
June-2015 Volume 11 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Advanced glycation end‑products affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras‑related C3 botulinum toxin substrate 1 signaling pathway

  • Authors:
    • Lei Lan
    • Yongsheng Han
    • Wei Ren
    • Jielong Jiang
    • Peng Wang
    • Zhao Hu
  • View Affiliations / Copyright

    Affiliations: Department of Nephrology, Affiliated Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Emergency Internal Medicine, Affiliated Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China, Department of Nephrology, Affiliated Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China
  • Pages: 4321-4326
    |
    Published online on: February 6, 2015
       https://doi.org/10.3892/mmr.2015.3317
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The present study aimed to determine the molecular mechanisms leading to the production of advanced glycation end‑products (AGEs) and their effect on the morphology and function of rat glomerular capillary endothelial cells (GECs). Primary rat GECs were treated with AGE‑modified human serum albumin (AGE‑HSA) and divided into groups according to AGE concentration and treatment time. The structure and distribution of cytoskeletal protein F‑actin and the cortical actin binding protein, cortactin, were analyzed using immunofluorescence and confocal microscopy. As the Ras‑related C3 botulinum toxin substrate 1 (Rac1) signaling pathway was previously identified to be involved in mediating the contraction of endothelial actin‑myosin activity, Rac1 was examined subsequent to treatment of the cells with the Rac1 agonist 2'‑O‑methyladenosine‑3',5'‑cyclic monophosphate (O‑Me‑cAMP) for 1 h using a pull‑down assay. Cell permeability was determined by the leakage rate of a fluorescein isothiocyanate fluorescent marker protein. AGE‑HSA treatment resulted in alterations in the structure and distribution of F‑actin and cortactin in a dose‑ and time‑dependent manner, while no effect was observed with HSA alone. The effect of AGE on the cytoskeleton was inhibited by the addition of O‑Me‑cAMP. AGE‑HSA significantly reduced the level of Rac1 activity (P<0.05); however, no effect was observed on total protein levels. Furthermore, AGE‑HSA treatment led to a significant increase in the permeability of endothelial cells (P<0.01), which was inhibited by O‑Me‑cAMP (P<0.01). The Rac1 signaling pathway is thus suggested to serve an important function in mediating AGE‑induced alterations in GEC morphology and function.

Introduction

Previous studies have demonstrated that an increase in glomerular capillary permeability is a key step leading to proteinuria in patients with diabetes and nephropathy (1). Glomerular capillary endothelial cells (GECs) constitute the first barrier preventing blood macromolecules, such as proteins, from passing through the endothelial wall (2–4). Therefore, the structure and distribution of GECs is closely associated with the permeability of the capillary. Previous studies have suggested that the reorganization and redistribution of the cytoskeleton protein F-actin and the cortical actin binding protein cortactin in endothelial cells is crucial to the increase in capillary permeability observed (5–7). In addition, the Ras-related C3 botulinum toxin substrate 1 (Rac1) signaling pathway has been identified to be involved in mediating the contraction of endothelial actin-myosin. This induces an alteration in cell morphology, destroying the cell-cell connections and forming the gap between cells (8–12), suggesting an association between the Rac1 signaling pathway and capillary permeability. It has been reported that advanced glycation end-products (AGEs) are involved in inducing alterations in the distribution of cytoskeletal proteins and endothelial cell permeability in diabetic patients with microvascular complications (13–16). However, the function of the Rac1 signaling pathway in this process remains elusive. In the present study, immunofluorescence staining and confocal microscopic analysis were conducted in order to determine the effect of AGEs on the structure and distribution of F-actin and cortactin in GECs. In addition, the levels of Rac1 activity were investigated using a pull-down assay, endothelial permeability was analyzed using a Transwell assay and the potential involvement of the Rac1 signaling pathway in this process was examined. The present study aimed to improve the understanding of the pathogenesis of nephropathic proteinuria in diabetics and provide novel therapeutic targets for diabetes and nephropathy.

Materials and methods

Materials

Dulbecco’s modified Eagle’s medium, MCDB131, trypsin and fetal bovine serum (FBS) were purchased from Gibco Life Technologies (Carlsbad, CA, USA). Vascular endothelial growth factor was purchased from BD Biosciences (San Jose, CA, USA) and fluorescein isothiocyanate (FITC)-phalloidin was obtained from Molecular Probes Life Technologies (Grand Island, NY, USA). FITC-labeled goat anti-rabbit antibody, human serum albumin (HSA) and FITC-bovine serum albumin were from Sigma-Aldrich (St. Louis, MO, USA). DAPI was purchased from Invitrogen Life Technologies (Carlsbad, CA, USA) and 2′-O-methyladenosine-3′,5′-cyclic monophosphate (O-Me-cAMP) was purchased from Aladdin Reagents Co., Ltd (Shanghai, China). Transwell was purchased from Corning Life Sciences (Tewksbury, MA, USA) and a Rac1 Activity Detection kit was purchased from EMD Millipore (Billerica, MA, USA). A Bradford kit was purchased from Shenneng Bocai Biotechnology Co., Ltd. (Shanghai, China).

Isolation and culture of GECs

The isolation and culture of primary GECs was conducted as previously described (17–19). All studies were approved by the Ethics Committee of Anhui Provincial Hospital (Hefei, China) for Animal Experiments and conformed to the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health. Primary GECs were isolated from the kidneys of two male Wistar rats (body weight, 80–120 g) (Animal Department of Anhui Medical University, China; certificate no. 003). Primary GECs were cultured in MCDB131 medium supplemented with 10% FBS in a humidified atmosphere with 5% CO2. All operations were performed under 10% chloral hydrate (Hechang Chemical Company, Wuhan, China) and all efforts were made to minimize suffering.

Preparation of AGE-modified HAS

AGE-HSA was prepared by incubating HSA with glucose, as previously described (20–23). The reaction system contained 1.5 g HSA and 3.0 g D-glucose (Meilun Bio, Dalian, China), which were dissolved in 10 ml phosphate-buffered saline (PBS; 0.2 mol; pH 7.4; Gibco Life Technologies) and filtered with 0.22 μm microporous membranes (EMD Millipore). The solution was then maintained in a container filled with nitrogen, which was sealed, protected from light and incubated at 37°C for three months. The unbound materials were removed using a dialysis bag (molecular weight, 10,000; Corning, Inc., Corning, NY, USA). The same procedure was completed without the addition of D-glucose for the control. The AGE value of the samples (1 mg/ml) was detected by fluorescence scanning (BX43; Olympus Corp., Tokyo, Japan) and samples were stored at −20°C.

Immunofluorescence staining

Staining was conducted as previously described (24–27). The slides were washed in PBS twice and fixed in 4% paraformaldehyde at room temperature for 30 min. Subsequently, the slides were treated with 0.1% Triton X-100 (Sangon Biotech Co., Ltd, Shanghai, China) for 15 min (F-actin staining). Subsequent to blocking with 1% bovine serum albumin (BSA; Sigma-Aldrich) for 1 h at room temperature, the samples were incubated with FITC-phalloidin for 1 h at room temperature in the dark (F-actin staining), or with rabbit anti-mouse monoclonal cortactin antibody (SAB1305513; 1:100) overnight at 4°C. For cortactin staining, samples were then incubated with DyLight 605-labeled goat anti-rabbit antibody (SAB4600398; 1:500) for 1 h at room temperature in the dark following washing three times with PBS for 5 min. Antibodies were obtained from Santa Cruz Biotechnology, Inc. (Beijing, China) and samples were incubated with antibodies for 2 h at room temperature. Glycerol (50%; Xilong Chemical Company, Guangzhou, China) was used to mount the glass slides with cells, and the images were captured using a confocal microscope.

Rac1 activity analysis

Racl activity was analyzed using a pull-down assay, as previously described (9,28). The protein was extracted using a chemical cleavage method, and the protein concentration was detected using the Bradford assay. Samples (50 μg) underwent SDS-PAGE (10%) and were subsequently transferred to polyvinylidene difluoride membranes (EMD Millipore). The membranes were incubated with RAC1-GTP antibody and were then incubated with horseradish peroxidase-conjugated secondary antibodies (Zhongshan Jinqiao Company, Beijing, China). The chemiluminescent images were obtained using a Kodak Image Station 2000R system (Kodak, Rochester, NY, USA) and the results were analyzed using ImageJ software version 1.44e (National Institutes of Health, Bethesda, MD, USA).

Cell permeability analysis

Using a previously reported method (29), GECs were seeded into the top compartment of a Transwell chamber with FITC-albumin (100 μl; 1 mg/ml; Sigma-Aldrich). Subsequent to incubation, the fluorescence intensity of samples was analyzed using a HTS-7000 Bio Assay Reader (BioAssay Systems, Hayward, CA, USA) with 495 nm excitation and 520 nm emission filters. The apparent permeability coefficient [(Pa) = (F/t)(1/A)(v/L)] was used, where F indicates the fluorescence intensity in the bottom chamber, t indicates time (sec), A is the membrane area (cm2), v is the solution volume in the bottom chamber and L indicates the fluorescence intensity in the top chamber. The results are expressed as a percentage [Pa% = (experimental Pa value/control Pa value) × 100%]. The experiments were repeated a minimum of five times.

Statistical analysis

Statistical analysis was performed using SPSS software, version 13.0 (SPSS, Inc., Chicago, IL, USA). All data are presented as the mean ± standard error and were analyzed by a one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of AGE-HSA on F-actin and cortactin morphologies in GECs

Under normal conditions, endothelial cells appear smooth and intact (30). F-actin is filamentous among the long axis and near cell junctions and is present in reticular, intact and continuous lines, predominantly in the edges of cells and the inner membranes. A small amount of reticular nuclear matrix is also present around the nucleus. Cortactin is predominantly distributed in the cytoplasm and is occasionally also present in the cell membrane. With an increase in AGE-HSA concentration or treatment time, the edge of the F-actin peripheral dense band was observed to become rough and irregular, with a jagged appearance. F-actin was observed to be diffusely distributed in cells and the number of stress fibers, composed of a single row of non-polar actin filaments, increased. The distribution of cytoplasmic cortactin became disorganized and it was unclear in the cortex and membrane. Cells became round and retracted when treated with AGE-HSA for 8 h at a concentration of 100 μg/ml; however, HSA alone did not produce these effects (Figs. 1 and 2).

Figure 1

AGE alters the morphology and distribution of F-actin and cortactin in a dose-dependent manner. Rat GECs were treated with different concentrations of AGE-HSA (25, 50 or 100 μg/ml) for 8 h. Cells cultured in pure MCDB131 medium (control) or with HSA (100 μg/ml) alone were designated as the controls. With increasing AGE-HAS concentration, the edge of the F-actin peripheral dense band was observed to become rough and irregular with a jagged appearance, F-actin was diffusely distributed in cells and the number of stress fibers increased. Cytoplasmic cortactin was unclear in the cortex and membrane and its distribution became disorganized. AGE, advanced glycation end-products; GEC, glomerular capillary endothelial cells; HSA, human serum albumin.

Figure 2

Time-dependent AGE-induced alterations to the morphology and distribution of F-actin and cortactin. GECs were treated with 100 μg/ml AGE-HSA for 2, 4 or 8 h. Cells cultured in pure MCDB131 medium (control) or with HSA (100 μg/ml) alone were designated as the controls. With increasing AGE-HAS treatment time, the edge of the F-actin peripheral dense band was observed to become rough and irregular with a jagged appearance, F-actin was diffusely distributed in cells and the number of stress fibers increased. Cytoplasmic cortactin was unclear in the cortex and membrane and its distribution became disorganized. AGE, advanced glycation end-products; GEC, glomerular capillary endothelial cells; HSA, human serum albumin.

Activation of Rac1 inhibits AGE-HSA-induced morphological alterations to F-actin and cortactin in GECs

The reconfiguration of the structure of F-actin, formation of central stress fibers and retraction in GECs induced by AGE-HSA was markedly inhibited by pre-treatment with O-Me-cAMP. In addition, similar inhibitory effects were observed in AGE-HSA-induced cortactin disorganization and cell retraction with O-Me-cAMP-pre-treatment. However, HSA alone did not produce this inhibitory effect (Fig. 3). These observations further suggested an involvement of the Rac1 signaling pathway in the development of AGE-induced morphological and structural alterations in GECs.

Figure 3

Effect of the Rac1 agonist O-Me-cAMP in regulating AGE-induced alterations in F-actin and cortactin morphology and distribution in endothelial cells. In the O-Me-cAMP group, cells were pre-treated with O-Me-cAMP (2 μmol/ml) for 60 min, then treated with AGE-HSA (100 μg/ml) for 8 h. The cells cultured in pure MCDB131 medium (control) or with HSA (100 μg/ml) alone were designated as the controls. AGE-induced F-actin structure reconstruction, the disorganized distribution of cortactin, altered cell morphology and the formation of stress fibers in endothelial cells were all markedly inhibited by O-Me-cAMP-pre-treatment. O-Me-cAMP, 2′-O-methyladenosine-3′,5′-cyclic monophosphate; AGE, advanced glycation end-products; GEC, glomerular capillary endothelial cells; HSA, human serum albumin.

Effect of AGE-HSA on the levels of Rac1 activity in GECs

The levels of Rac1 activity (but not total Rac1 levels) in the AGE-HSA (100 μg/ml) treatment group were significantly reduced compared with those in the control group (P=0.002), whereas HSA alone did not produce this effect (Fig. 4). These results suggested that the Rac1 signaling pathway is important in the mediation of AGE-induced functional alterations in endothelial cells.

Figure 4

Effect of AGE on the levels of Rac1 activity in GECs. AGE-HSA (100 μg/ml) treatment for 8 h significantly reduced the levels of Rac1 activity compared with controls, but did not affect the levels of total protein. #P<0.05 vs. control group. AGE, advanced glycation end-products; GEC, glomerular capillary endothelial cells; HSA, human serum albumin; GTP, guanosine triphosphate.

Rac1 agonist inhibits the AGE-HSA-induced increase in GEC permeability

The permeability of GECs to FITC-BSA was significantly increased with AGE-HSA-treatment (P<0.05), but not with HSA alone (P>0.05). This effect was inhibited by O-Me-cAMP, as demonstrated by reduction in Pa from 189.32±6.16 to 128.52±3.53% subsequent to treatment with O-Me-cAMP (Fig. 5).

Figure 5

Effect of O-Me-cAMP on mediation of AGE-induced alterations in endothelial cell permeability. Compared with the control group, treatment with AGE-HSA (100 μg/ml) for 8 h significantly increased permeability in endothelial cells (P<0.05), which was inhibited by O-Me-cAMP. #P<0.05 vs. control; *P<0.05 vs. AGE-HSA. O-Me-cAMP, 2′-O-methyladenosine-3′,5′-cyclic monophosphate; AGE, advanced glycation end-products; GEC, glomerular capillary endothelial cells; HSA, human serum albumin; BSA, bovine serum albumin.

Discussion

The initial step in the development of diabetes and nephropathy is the structural and functional impairment of GECs, which induces glomerular capillary lesions and leads to disease progression (31,32). The increase in glomerular capillary permeability is considered to indicate the development of diabetes and nephropathy and leads to the development of pathological proteinuria (33). The proximal damage among cells is considered to be the basis for the increase in endothelial cell gap formation and vascular permeability (2,34–36). A number of studies have demonstrated that the alterations in cellular morphology and the distribution of cytoskeletal proteins is closely associated with the integrity of the endothelial cell-cell connections (37,38). The AGE content in diabetic patients has been observed to be significantly increased, which may induce damage to GEC structure and function (39–41). Additional studies have demonstrated that AGE increases the permeability of umbilical vein endothelial cells and induces alterations in the distribution and morphology of cytoskeletal proteins (8,11,12,14). To mimic the pathological process of glomerular capillary endothelial damage in diabetes and nephropathic patients, primary GECs were used in the present study. The effects of AGE on the distribution and morphology of F-actin and cortactin in GECs were investigated and it was determined whether or not these processes were mediated by the Rac1 signaling pathway. Rac1 is a member of the Ras protein superfamily and belongs to the Rho family of guanosine triphosphatases (42). Rac1 has multiple functions, including controlling cellular morphology, actin movement, transcriptional activation and apoptotic signals (43–46). Rac1 has two active forms, including an active form bound to guanosine triphosphate (GTP) on the cell membrane and an inactive form bound to GTP in the cytoplasm. The two forms can change as a result of upstream stimuli, Rac 1 combining with GTP on the cell membrane is activated, whereas on the cytoplasm it is inactivated, which in turn regulate the functions of downstream effectors.

It has been demonstrated that Rac1 can be activated by specific extracellular signals, which in turn induce actin cytoskeleton-directed assembly, resulting in characteristic morphological alterations, including cell stretch (47), an increase in cortical actin polymerization (48) and an enhancement of connections between cells (10). Therefore, the Rac1 signaling pathway is suggested to be necessary for maintaining the stability of vascular endothelial cell connections. Previous studies have suggested that activation of the Rac1 signaling pathway can promote cortactin translocation to the plasma membrane and cortex, thus inhibiting cell collapse and gap-formation and strengthening cell-cell connections (49–51). The mechanism for strengthening these connections is frequently associated with the increase in cortical actin polymerization, cortical cortactin and the enhancement of binding to the cortical actin cytoskeleton. Thus, cortical actin assembly is suggested to be closely associated with cortactin.

In the present study, the observations suggested that the AGE-induced increase in GEC permeability was closely associated with inhibition of Rac1 activity. It was observed that the F-actin peripheral dense band became thicker and disorganized, the number of central stress fibers increased, the expression levels of cortactin in cell membranes were reduced, the boundaries of cells were unclear and cells retracted and deformed upon treatment with AGE in a time- and dose-dependent manner (Figs. 1 and 2). These alterations are associated with the damage to endothelial cell integrity and the increase in permeability. The pull-down assay was used to investigate Rac1 activity upon treatment with different concentrations of AGE-HSA, and it was observed that AGE-HSA was able to significantly reduce Rac1 activity (P<0.05; Fig. 4). This suggested an important involvement for Rac1 in the mediation of functional alterations in GECs induced by AGE. In addition, the present study demonstrated that with O-Me-cAMP pre-treatment, AGE-induced alterations in cell morphology and stress fiber-formation (Fig. 3), in addition to increased GEC permeability, were significantly inhibited (P<0.05; Fig. 5).

In conclusion, the results of the present study suggested that Rac1 signaling is important in mediating AGE-induced morphological and functional alterations in GECs. This may aid in the development of novel therapeutic targets for microvascular complications in patients with advanced diabetes. Furthermore, it was observed that O-Me-cAMP was not able to completely reverse AGE-induced alterations, including the disorganization of F-actin and cortactin distribution and morphology, and the increase in cell permeability. This suggested that in addition to the Rac1 signaling pathway, other pathways may be involved in the pathological processes induced by AGE, which require further investigation.

References

1 

Ying WZ, Lin SY and Qiu CL: Study of permeability of the glomerular capillary wall in human membranous nephropathy. Zhonghua Nei Ke Za Zhi. 25:227–231. 2541986.In Chinese.

2 

Satchell SC and Braet F: Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol. 296:F947–F956. 2009. View Article : Google Scholar : PubMed/NCBI

3 

Myers BD: Pathophysiology of proteinuria in diabetic glomerular disease. J Hypertens Suppl. 8:S41–S46. 1990. View Article : Google Scholar : PubMed/NCBI

4 

Remuzzi G and Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int. 38:384–394. 1990. View Article : Google Scholar : PubMed/NCBI

5 

Schnoor M, Lai FP, Zarbock A, et al: Cortactin deficiency is associated with reduced neutrophil recruitment but increased vascular permeability in vivo. J Exp Med. 208:1721–1735. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Romero IA, Radewicz K, Jubin E, Michel CC, Greenwood J, Couraud PO and Adamson P: Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett. 344:112–116. 2003. View Article : Google Scholar : PubMed/NCBI

7 

Dudek SM and Garcia JG: Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol (1985). 91:1487–1500. 2001.

8 

Spindler V, Peter D, Harms GS, Asan E and Waschke J: Ultrastructural analysis reveals cAMP-dependent enhancement of microvascular endothelial barrier functions via Rac1-mediated reorganization of intercellular junctions. Am J Pathol. 178:2424–2436. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Peng H, Wang C, Ye ZC, et al: How increased VEGF induces glomerular hyperpermeability: a potential signaling pathway of Rac1 activation. Acta Diabetol. 47(Suppl 1): 57–63. 2010. View Article : Google Scholar

10 

Spindler V, Schlegel N and Waschke J: Role of GTPases in control of microvascular permeability. Cardiovasc Res. 87:243–253. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Semina EV, Rubina KA, Rutkevich PN, Voyno-Yasenetskaya TA, Parfyonova YV and Tkachuk VA: T-cadherin activates Rac1 and Cdc42 and changes endothelial permeability. Biochemistry (Mosc). 74:362–370. 2009. View Article : Google Scholar

12 

Mehta D and Malik AB: Signaling mechanisms regulating endothelial permeability. Physiol Rev. 86:279–367. 2006. View Article : Google Scholar

13 

Guo X, Wang L, Chen B, et al: ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability. Am J Physiol Heart Circ Physiol. 297:H238–H246. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Guo XH, Huang QB, Chen B, et al: Advanced glycation end products induce actin rearrangement and subsequent hyperpermeability of endothelial cells. APMIS. 114:874–883. 2006. View Article : Google Scholar

15 

Guo XH, Huang QB, Chen B, Wang SY, Hou FF and Fu N: Mechanism of advanced glycation end products-induced hyperpermeability in endothelial cells. Sheng Li Xue Bao. 57:205–210. 2005.In Chinese. PubMed/NCBI

16 

Sheikpranbabu S, Haribalaganesh R, Lee KJ and Gurunathan S: Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability. Biochimie. 92:1040–1051. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Akis N and Madaio MP: Isolation, culture, and characterization of endothelial cells from mouse glomeruli. Kidney Int. 65:2223–2227. 2004. View Article : Google Scholar : PubMed/NCBI

18 

Rops AL, van der Vlag J, Jacobs CW, et al: Isolation and characterization of conditionally immortalized mouse glomerular endothelial cell lines. Kidney Int. 66:2193–2201. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Laulajainen T, Julkunen I, Haltia A, Knuutila S, Miettinen A and Holthöfer H: Establishment and characterization of a rat glomerular endothelial cell line. Lab Invest. 69:183–192. 1993.PubMed/NCBI

20 

Glomb MA and Monnier VM: Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem. 270:10017–10026. 1995. View Article : Google Scholar : PubMed/NCBI

21 

Nagai R, Unno Y, Hayashi MC, Masuda S, Hayase F, Kinae N and Horiuchi S: Peroxynitrite induces formation of N(epsilon)-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: novel pathways for protein modification by peroxynitrite. Diabetes. 51:2833–2839. 2002. View Article : Google Scholar : PubMed/NCBI

22 

Hou FF, Boyce J, Chertow GM, Kay J and Owen WF Jr: Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. J Am Soc Nephrol. 9:277–283. 1998.PubMed/NCBI

23 

Hou FF, Miyata T, Boyce J, et al: beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int. 59:990–1002. 2001. View Article : Google Scholar : PubMed/NCBI

24 

Eiselein L, Wilson DW, Lamé MW and Rutledge JC: Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am J Physiol Heart Circ Physiol. 292:H2745–H2753. 2007. View Article : Google Scholar : PubMed/NCBI

25 

Zheng HZ, Zhao KS, Zhou BY and Huang QB: Role of Rho kinase and actin filament in the increased vascular permeability of skin venules in rats after scalding. Burns. 29:820–827. 2003. View Article : Google Scholar : PubMed/NCBI

26 

Wu H and Parsons JT: Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol. 120:1417–1426. 1993. View Article : Google Scholar : PubMed/NCBI

27 

Paradis H, Islam T, Tucker S, Tao L, Koubi S and Gendron RL: Tubedown associates with cortactin and controls permeability of retinal endothelial cells to albumin. J Cell Sci. 121:1965–1972. 2008. View Article : Google Scholar : PubMed/NCBI

28 

Ando K, Ishibashi T, Ohkawara H, et al: Crucial role of membrane type 1 matrix metalloproteinase (MT1- MMP) in RhoA/Rac1-dependent signaling pathways in thrombin- stimulated endothelial cells. J Atheroscler Thromb. 18:762–773. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Boutoille D, Marechal X, Pichenot M, Chemani C, Guery B and Faure K: FITC-albumin as a marker for assessment of endothelial permeability in mice: comparison with 125I-albumin. Exp Lung Res. 35:263–271. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Kajiya M, Komatsuzawa H, Papantonakis A, et al: Aggregatibacter actinomycetemcomitans Omp29 is associated with bacterial entry to gingival epithelial cells by F-actin rearrangement. PLoS One. 6:e182872011. View Article : Google Scholar : PubMed/NCBI

31 

Swärd P and Rippe B: Acute and sustained actions of hyperglycaemia on endothelial and glomerular barrier permeability. Acta Physiol (Oxf). 204:294–307. 2012. View Article : Google Scholar

32 

Balakumar P, Chakkarwar VA, Krishan P and Singh M: Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? Biomed Pharmacother. 63:171–179. 2009. View Article : Google Scholar

33 

Thomas MC: Pathogenesis and progression of proteinuria. Contrib Nephrol. 170:48–56. 2011. View Article : Google Scholar : PubMed/NCBI

34 

Dane MJ, van den Berg BM, Avramut MC, et al: Glomerular endothelial surface layer acts as a barrier against albumin filtration. Am J Pathol. 82:1532–1540. 2013. View Article : Google Scholar

35 

Stewart RJ and Marsden PA: Vascular endothelial cell activation in models of vascular and glomerular injury. Kidney Int Suppl. 45:S37–S44. 1994.PubMed/NCBI

36 

Koike K, Aiboshi J, Shinozawa Y, Sekine K, Endo T and Yamamoto Y: Correlation of glomerular permeability, endothelial injury, and postoperative multiple organ dysfunction. Surg Today. 34:811–816. 2004. View Article : Google Scholar : PubMed/NCBI

37 

Bates DO: Vascular endothelial growth factors and vascular permeability. Cardiovasc Res. 87:262–271. 2010. View Article : Google Scholar : PubMed/NCBI

38 

Bogatcheva NV and Verin AD: The role of cytoskeleton in the regulation of vascular endothelial barrier function. Microvasc Res. 76:202–207. 2008. View Article : Google Scholar : PubMed/NCBI

39 

Soulis T, Thallas V, Youssef S, et al: Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia. 40:619–628. 1997. View Article : Google Scholar : PubMed/NCBI

40 

Hori O, Yan SD, Ogawa S, Kuwabara K, Matsumoto M, Stern D and Schmidt AM: The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol Dial Transplant. 11(Suppl 5): 13–16. 1996. View Article : Google Scholar : PubMed/NCBI

41 

Yamagishi S: Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol. 46:217–224. 2011. View Article : Google Scholar

42 

Bond M, Wu YJ, Sala-Newby GB and Newby AC: Rho GTPase, Rac1, regulates Skp2 levels, vascular smooth muscle cell proliferation, and intima formation in vitro and in vivo. Cardiovasc Res. 80:290–298. 2008. View Article : Google Scholar : PubMed/NCBI

43 

Szczepanowska J: Involvement of Rac/Cdc42/PAK pathway in cytoskeletal rearrangements. Acta Biochim Pol. 56:225–234. 2009.PubMed/NCBI

44 

Pai SY, Kim C and Williams DA: Rac GTPases in human diseases. Dis Markers. 29:177–187. 2010. View Article : Google Scholar : PubMed/NCBI

45 

Williams LM, Lali F, Willetts K, et al: Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. Mol Immunol. 45:2446–2454. 2008. View Article : Google Scholar : PubMed/NCBI

46 

Mondal S, Ghosh-Roy S, Loison F, et al: PTEN negatively regulates engulfment of apoptotic cells by modulating activation of Rac GTPase. J Immunol. 187:5783–5794. 2011. View Article : Google Scholar : PubMed/NCBI

47 

Chang F, Lemmon C, Lietha D, Eck M and Romer L: Tyrosine phosphorylation of Rac1: a role in regulation of cell spreading. PLoS One. 6:e285872011. View Article : Google Scholar : PubMed/NCBI

48 

Jacobson JR, Dudek SM, Singleton PA, Kolosova IA, Verin AD and Garcia JG: Endothelial cell barrier enhancement by ATP is mediated by the small GTPase Rac and cortactin. Am J Physiol Lung Cell Mol Physiol. 291:L289–L295. 2006. View Article : Google Scholar : PubMed/NCBI

49 

Weed SA, Du Y and Parsons JT: Translocation of cortactin to the cell periphery is mediated by the small GTPase Rac1. J Cell Sci. 111:2433–2443. 1998.PubMed/NCBI

50 

Adamson RH, Sarai RK, Altangerel A, Thirkill TL, Clark JF and Curry FR: Sphingosine-1-phosphate modulation of basal permeability and acute inflammatory responses in rat venular microvessels. Cardiovasc Res. 88:344–351. 2010. View Article : Google Scholar : PubMed/NCBI

51 

Maharjan S, Kim K, Agrawal V, et al: Sac-1004, a novel vascular leakage blocker, enhances endothelial barrier through the cAMP/Rac/cortactin pathway. Biochem Biophys Res Commun. 435:420–427. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Lan L, Han Y, Ren W, Jiang J, Wang P and Hu Z: Advanced glycation end‑products affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras‑related C3 botulinum toxin substrate 1 signaling pathway. Mol Med Rep 11: 4321-4326, 2015.
APA
Lan, L., Han, Y., Ren, W., Jiang, J., Wang, P., & Hu, Z. (2015). Advanced glycation end‑products affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras‑related C3 botulinum toxin substrate 1 signaling pathway. Molecular Medicine Reports, 11, 4321-4326. https://doi.org/10.3892/mmr.2015.3317
MLA
Lan, L., Han, Y., Ren, W., Jiang, J., Wang, P., Hu, Z."Advanced glycation end‑products affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras‑related C3 botulinum toxin substrate 1 signaling pathway". Molecular Medicine Reports 11.6 (2015): 4321-4326.
Chicago
Lan, L., Han, Y., Ren, W., Jiang, J., Wang, P., Hu, Z."Advanced glycation end‑products affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras‑related C3 botulinum toxin substrate 1 signaling pathway". Molecular Medicine Reports 11, no. 6 (2015): 4321-4326. https://doi.org/10.3892/mmr.2015.3317
Copy and paste a formatted citation
x
Spandidos Publications style
Lan L, Han Y, Ren W, Jiang J, Wang P and Hu Z: Advanced glycation end‑products affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras‑related C3 botulinum toxin substrate 1 signaling pathway. Mol Med Rep 11: 4321-4326, 2015.
APA
Lan, L., Han, Y., Ren, W., Jiang, J., Wang, P., & Hu, Z. (2015). Advanced glycation end‑products affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras‑related C3 botulinum toxin substrate 1 signaling pathway. Molecular Medicine Reports, 11, 4321-4326. https://doi.org/10.3892/mmr.2015.3317
MLA
Lan, L., Han, Y., Ren, W., Jiang, J., Wang, P., Hu, Z."Advanced glycation end‑products affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras‑related C3 botulinum toxin substrate 1 signaling pathway". Molecular Medicine Reports 11.6 (2015): 4321-4326.
Chicago
Lan, L., Han, Y., Ren, W., Jiang, J., Wang, P., Hu, Z."Advanced glycation end‑products affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras‑related C3 botulinum toxin substrate 1 signaling pathway". Molecular Medicine Reports 11, no. 6 (2015): 4321-4326. https://doi.org/10.3892/mmr.2015.3317
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team